Mounier C, Guilhot F, Garnache F, Berthou C, Kara-Slimane F, Harousseau J-L.
Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study
in adultde novoacute myelogenous leukemia. Blood 2003;102:1202–1210.
Sonneveld P, Suciu S, Weijermans P, Beksac M, Neuwirtova R, Solbu G, Lokhorst H,
van der Lelie J, Dohner H, Gerhartz H, Segeren CM, Willemze R, Lowenberg B.
Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD)
compared with VAD alone; in patients with advanced refractory multiple myeloma:
an EORTC-HOVON randomized phase III study (06914). Br J Haematol
2001;115:895–902.
Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DKF, Borst P,
Nooijen WJ, Beijnen JH, van Tellingen O, Limited oral bioavailability and active
epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.
PNAS 1997;94:2031–2035.
Sparreboom A, Planting AS, Jewell RC, van der Burg ME, van der Gaast A, de Bruijn
P, Loos WJ, Nooter K, Chandler LH, Paul EM, Wissel PS, Verweij J. Clinical
pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor
of MDR1 P-glycoprotein. Anticancer Drugs 1999;10:719–728.
Sparreboom A, Danesi R, Ando Y, Chan J, Figg WD. Pharmacogenomics of ABC
transporters and its role in cancer chemotherapy. Drug Resist Updat 2003;6:71–84.
Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately
regulates drug metabolism and efflux. Nat Med (New York, NY, United States)
2001;7:584–590.
Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting
multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219–234.
Tabas LB, Dantzig AH. A high-throughput assay for measurement of multidrug
resistance protein-mediated transport of leukotriene C4 into membrane vesicles.
Anal Biochem 2002;310:61–66.
Tahara H, Kusuhara H, Fuse E, Sugiyama Y. P-glycoprotein plays a major role in the
efflux of fexofenadine in the small intestine and blood–brain barrier, but only a
limited role in its biliary excretion. Drug Metab Dispos 2005;33:963–968.
Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T,
Endou H. Characterization of methotrexate transport and its drug interactions with
human organic anion transporters. J Pharmacol Exp Ther 2002;302: 666–671.
ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation
vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 2003;42:665–685.
Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular
localization of the multidrug-resistance gene product P-glycoprotein in normal
human tissues. Proc Nat Acad Sci USA 1987;84:7735–7738.
Thoern M, Finnstroem N, Lundgren S, Rane A, Loeoef L. Cytochromes P450 and
MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin
Pharmacol 2005;60:54–60.
Tokui T, Nakai D, Nakagomi R, Yawo H, Abe T, Sugiyama Y. Pravastatin, an HMG-
CoA reductase inhibitor, is transported by rat organic anion transporting
polypeptide, oatp2. Pharm Res 1999;16:904–908.
Tsuruoka S, Ioka T, Wakaumi M, Sakamoto K, Ookami H, Fujimura A. Severe
arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with
REFERENCES 199